ARTICLE |
Correspondence to: Shelby L. Berger, Building 8, Room 311A, NIH, Bethesda, MD 20892-0480.
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Prothymosin is a small, unfolded, negatively charged, poorly antigenic mammalian protein with a potent nuclear localization signal. Although it is apparently essential for growth, its precise function is unknown. We examined the location and behavior of the protein bearing different epitope tags using in situ immunolocalization in COS-1 and NIH3T3 cells. Tagged prothymosin
appeared to be punctate and widely dispersed throughout the nucleus, with the exception of the nucleolus. A tiny cytoplasmic component, which persisted in the presence of cycloheximide and actinomycin D during interphase, became pronounced immediately before, during, and after mitosis. When nuclear uptake was abrogated, small tagged prothymosin
molecules, but not prothymosin
fused to ß-galactosidase, accumulated significantly in the cytoplasm. Tagged prothymosin
shared domains with mobile proteins such as Ran, transportin, and karyopherin ß, which also traverse the nuclear membrane, and co-localized with active RNA polymerase II. Mild digitonin treatment resulted in nuclei devoid of prothymosin
. The data do not support tight binding to any nuclear component. Therefore, we propose that prothymosin
is a highly diffusible bolus of salt and infer that it facilitates movement of charged molecules in highly charged environments within and near the nucleus. (J Histochem Cytochem 48:13411355, 2000)
Key Words:
prothymosin , nucleus, mitosis, charged molecules
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
THE FUNCTION of prothymosin remains unclear despite many attempts to determine both its binding partners and its cellular location. Although the levels of the protein and its mRNA unquestionably increase in proliferating mammalian cells (
does, where it does it, and what other macromolecules participate are questions with multiple unsatisfactory answers. The difficulties stem from three attributes: (a) Prothymosin
is extremely acidic, with a net negative charge of
40 units (
12 kD (
an easy target for basic proteins in binding studies performed in vitro. The relevance of binding data is, accordingly, problematic. (b) Antibodies raised to prothymosin
or peptides derived from it are invariably low in titer and broad in specificity. Such antibodies, particularly those directed against the N-terminus, crossreact with materials from crabs, insects, protozoans, fungi, and bacteria (
or related proteins, and homologous proteins in bacteria and homologous genes in a broad swath of the evolutionary spectrum up to and including reptiles have not been forthcoming (
does not have an activity that can be used in vivo or in vitro to assess its functional integrity.
The published binding partners of prothymosin in vitro include histone H1 and core histones (
(
itself partitions to the aqueous phase and behaves chemically much like an RNA (
stimulates the phosphorylation of translation factor eEF2 during mitosis (
During its 15-year history, prothymosin has been localized to several sectors both inside and outside the cell. As the name suggests, prothymosin
was once believed to be a precursor of a putative thymic hormone, thymosin
1 (
in blood (
was isolated, the absence of a signal peptide, together with the presence of a consensus nuclear localization signal, strongly implied a nuclear destination (
or a derived peptide bearing the consensus bipartite basic cluster of amino acids near the carboxyl terminus was able to drag covalently-attached non-nuclear proteins into the nucleus (
fused to ß-galactosidase to remain nuclear (
labeled with Bolton Hunter reagent on the e-NH2 groups of lysine residues transported a significant fraction to the nucleus (
1 recognized material in the cytoplasm of epithelial cells in the subcapsullary and medullary zones of the thymus and, at the electron microscopic level, stained large and small cytoplasmic vacuoles (
1 highlighted immunoreactive material in the nuclei of bile duct cells but not hepatocytes (
was almost invariably cytoplasmic (
.
It is now widely accepted that prothymosin is a nuclear protein (
under a wide variety of metabolic conditions. In this endeavor, we chose to employ the protein tagged with several different epitopes and a series of antibodies that recognize them. Antibodies to prothymosin
itself were avoided because without supportive information they are suspect and unsuitable for work in situ. We have also investigated potential neighbors of prothymosin
. Our experiments suggest that the protein is overwhelmingly nuclear, highly mobile, intermittently cytoplasmic, and continuously pumped into the nucleus. It is apparently not tightly tethered to any macromolecular species either in the nucleus or in the cytoplasm. To explain the data, we propose that prothymosin
is a freely diffusible bolus of concentrated salt that facilitates movement of charged molecules in highly charged environments near and within the nucleus.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cell Culture
Origin-defective SV40-transformed green monkey kidney cells (COS-1) were grown in Dulbecco's modified Eagle's medium (DMEM) from Biofluids (catalog #172; Rockville, MD) supplemented with 10% heat-inactivated fetal calf serum (Hyclone; Logan, UT), 2 mM L-glutamine, 90 U/ml of penicillin, 90 µg/ml of streptomycin, and 0.22 µg/ml of amphotericin B (Life Technologies; Gaithersburg, MD). NIH3T3 cells were cultured similarly except for the substitution of calf serum for fetal calf serum. All cultures were incubated in a humidified environment containing 5% CO2 at 37C unless noted otherwise. For inhibitor studies, cells were cultured in the presence of 5 µg/ml of actinomycin D or 100 µg/ml of cycloheximide. Stock solutions of actinomycin D were prepared in ethanol; accordingly, samples and controls contained 0.25% (v/v) solvent.
Plasmids and Transfection Procedures
Plasmid pBC12BIProG 6-his, which codes for prothymosin with six histidine residues affixed to the carboxyl terminus (
, and E. coli ß-galactosidase (
with an N-terminal FLAG sequence, called pFLAG 60, was constructed by removing a Hind IIIBam HI fragment from pBC12BIProG, the prothymosin
gene behind the RSV LTR in an expression plasmid (
codons 26, i.e., ser-asp-ala-ala-and part of val. Because the prothymosin
codons were identical to those of the original gene, the cleaved Acc I site was preserved and the downstream prothymosin
region was fused in frame. After ligation to the Acc-Bam H1 fragment, the new Hind IIIBam HI fragment was inserted into the plasmid; the resultant construct consisted of a fused FLAGprothymosin
gene with much of the 5' untranslated region of the prothymosin
gene replaced with the new material. The clone was sequenced to ensure that it was correct.
Both COS-1 cells and NIH3T3 cells were transiently transfected. COS cells were plated in Lab-Tek double-well chamber slides (#178565; Nalge Nunc International, Naperville, IL) at 3 x 104 cells per well and incubated overnight in complete medium. Transfection was accomplished with 250 ng of plasmid/well using LipofectAMINE (Life Technologies) and instructions provided by the manufacturer. Cells were allowed to express the ectopic histidine-tagged gene for 6 hr before experiment-specific manipulations were initiated, except in the studies described in Fig 7, where a new preparation of pBC12BIProG 6-his required ~12 hr of expression to achieve similar product levels. The gene for prothymosin fused to ß-galactosidase was expressed for a minimum of 24 hr.
|
|
|
|
|
|
|
For NIH3T3 cells, transfections were performed in 60-mm dishes; cells were seeded at 4 x 105 cells/dish and allowed to grow overnight, rinsed with DMEM, and transfected with 2 µg of plasmid using LipofectAMINE with PLUS reagent (Life Technologies) and a protocol provided by the manufacturer. After a 2448-hr incubation to allow expression, cells were trypsinized (
Permeabilization of Cells
Permeabilization was carried out using minor modifications of the technique described by
Cells grown on microscope slides were permeabilized with -toxin by bathing the monolayers in a solution of 300 hemolytic U/ml of
-toxin (#616385, Calbiochem) in transport buffer for 5 min on ice. Immediately thereafter, cells were incubated at 37C for 30 min in complete culture medium or complete medium containing 1 mM adenosine 5'-O-(3-thiotriphosphate) and 1 mM guanosine 5'-O-(3-thiotriphosphate) (ATP
S and GTP
S) purchased from Sigma Chemical (St Louis, MO).
Immunostaining
Antibody treatments were performed on cells that were rinsed free of medium with PBS. Then the cells were fixed in PBS containing 3% paraformaldehyde in PBS for 30 min, permeabilized with 100% methanol, blocked overnight at 4C in blocking buffer [PBS containing 1% bovine serum albumin, 2% (v/v) non-immune horse serum, and 3% (v/v) non-immune goat serum], and stained with primary antibodies. Primary antibodies that recognized epitope tags on prothymosin were mouse monoclonal antibody to ß-galactosidase (#63363; ICN Biomedicals), mouse monoclonal antibody to pentahistidine (#34660; Qiagen, Valencia, CA), and anti-FLAG M2 antibody (Kodak; Rochester, NY). Other primary antibodies and their sources were as follows: mouse monoclonal antibody against the phosphorylated carboxyl terminal domain of RNA polymerase II, Covance (#MMS-134R; Richmond, CA); mouse monoclonal antibody against SC-35, BD PharMingen (#65201A; San Diego, CA); mouse monoclonal antibody against histone H1 (#382152; Calbiochem); and mouse monoclonal antibodies against karyopherin ß, Ran, and transportin (# K48020, R32620, and T57720, respectively) from BD Transduction Laboratories (Lexington, KY). With the exception of the co-localization experiments with nuclear proteins (Fig 7), the secondary antibodies were either rhodamine[tetramethylrhodamine isothiocyanate (TRITC)]-conjugated or fluorescein-[fluorescein isothiocyanate (FITC)]-conjugated AffiniPure goat anti-mouse IgG (Jackson ImmunoResearch Laboratories; West Grove, PA). For Fig 7, the dye-conjugated goat anti-mouse secondary antibodies were included in the Alexa Fluor 488 (green) or the Alexa Fluor 594 (red) Signal Amplification Kits (# 11054 and 11067, respectively; Molecular Probes, Eugene, OR). Samples were stained with antibodies diluted in blocking buffer for 1 hr at room temperature, washed three times for 10 min each with blocking buffer, and stained with diluted dye-conjugated antibodies. In some cases, tertiary antibodies, also supplied with the kits from Molecular Probes, were used to amplify weak signals. Coverslips were mounted using VECTASHIELD mounting medium with 4', 6-diamidino-2-phenylindole (DAPI) (#H1200; Vector Laboratories, Burlingame, CA).
Microscopy and Image Analysis
Slides were viewed with a Leica DMRB fluorescence microscope (Leica; Rockleigh, NJ) and photographed using the SenSys camera system (Photometrics; Munich, Germany). The images were captured in gray scale and pseudocolored using the IP Lab Spectrum P software (Signal Analytics; Vienna, VA).
Confocal microscopy was performed with a Zeiss LSM 410 instrument using a krypton/argon laser for fluorescence excitation at 488 nm and 568 nm for FITC and TRITC, respectively. Images were captured using a pinhole setting of 1 AIRY unit for an optical section of 0.7 µm.
Final images were assembled in Adobe Photoshop 5.0.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Location of Prothymosin in Cells at Interphase and During M-phase
The location of prothymosin in the cell was examined using in situ immunolocalization. COS-1 and NIH3T3 cells were transfected with genes for a series of epitope-tagged prothymosin
proteins, shown diagramatically in Fig 1f, with the prothymosin
sequences colored green. Three variants bearing epitopes differing in size, charge, and position with respect to prothymosin
were generated as follows. Prothymosin
tagged with six histidine residues made use of a small basic epitope covalently attached to the carboxyl terminus (Fig 1a and Fig 1b). Prothymosin
with FLAG employed an acidic epitope consisting of seven amino acids inserted immediately downstream of the amino-terminal methionine residue, which is cleaved from normal prothymosin
(Fig 1e). Finally, we used prothymosin
in a chimera consisting of 40 amino acids of E. coli xanthine-guanine phosphoribosyl transferase (Ecogpt), 28 amino acids from E. coli tryptophanyl-tRNA synthetase (trpS), and the entirety of prothymosin
fused to a very large bacterial protein without a nuclear localization signal of its own, i.e., ß-galactosidase (Fig 1c and Fig 1d). This molecule, abbreviated prothymosin
/ß-gal, is bulky enough to be unable to diffuse passively in either direction through the nuclear pore. As shown in Fig 1, prothymosin
in NIH3T3 cells (left) or in COS-1 cells (right) was overwhelmingly nuclear regardless of whether the secondary antibody used for visualization was conjugated to rhodamine (red) or to fluorescein (green). It was also clear that the nuclear location of prothymosin
in the cell was independent of the nature of the epitope tag, its size, or its position within the expressed chimeric protein. In all cases, with the exception of the mitotic cell shown in Fig 1c, tagged prothymosin
appeared punctate but widely dispersed throughout the nucleus. When overexpressed, the tagged protein colored nuclei almost uniformly (data not shown), with the exception of the nucleolus, which remained essentially free of stained prothymosin
under all circumstances. The minor variations that were observed among these systems in Fig 1 can be ascribed to fluctuations in the intensity of the stain coupled with a range in transfection efficiencies and expression levels.
Expression of chimeras depends on the vector and the host. Transfected COS cells, which are capable of producing a huge excess of prothymosin /6-his in 2472 hr owing to the presence of large T-antigen in the cells and an SV40 origin of replication in the plasmid, generate detectable amounts only 2 hr after introduction of the DNA (data not shown). Our cells were examined 6 hr after transfection to limit the amount of tagged protein to about one quarter to one fifth that of its native counterpart. In contrast, FLAG/prothymosin
in NIH3T3 cells is synthesized at lower levels because the GC-rich region downstream of the TATA box was deleted. However, by 48 hr sufficient protein is accumulated in transfected cells to permeate the nucleus. Prothymosin
/ß-gal expression suffers from an added deficiency. It makes use of a plasmid, pCH110, which not only lacks SV40 sequences but also contains a weaker promoter than that found in pBC12BI, the parent plasmid used for the FLAG and 6-his constructs. The robust expression of prothymosin
/6-his in COS cells, a transfection efficiency near 100%, and the ability to modulate the level of ectopic protein by varying the time of expression made this combination our preferred system in subsequent experiments. It is also worth noting that our laboratory has previously shown that prothymosin
/6-his is phosphorylated and dephosphorylated normally in COS cells (
The one cell that differed qualitatively from all others in Fig 1 was a mitotic cell. Although some investigators have assumed that prothymosin is released into the cytoplasm during mitosis, this is the first experimental illustration of the event. In Fig 1c, attached daughter cells in which cytokinesis and the reconstitution of the nuclei are virtually complete contained significant levels of cytoplasmic prothymosin
as well as a perinuclear accumulation of the protein, presumably poised for re-entry. To obtain further insight into the function of prothymosin
by exploring its location in cells under different conditions, we investigated COS cells throughout mitosis and compared the position of prothymosin
/6-his stained with rhodamine (Fig 2, Column 1) to that of DNA stained with DAPI (Fig 2, Column 2). The images are presented in mitotic order, with a cell in late prophase at the top, a cell in telophase at the bottom, and intermediate stages between the two. For ease in localization, the superimposed images of DNA and prothymosin
/6-his are shown in Fig 2, Column 3. The top two examples (Fig 2, Rows a and b) illustrate cells in interphase, which were lightly stained with DAPI, together with cells containing the condensed chromatin characteristic of prophase, which appeared much brighter in Fig 2, Column 2. In these interphase cells, the antibody for pentahistidine, which recognizes the chimeric prothymosin
, appeared to occupy the same area as the light DAPI stain (Fig 2, Column 2, Rows a and b). This perception was reinforced when the two images were overlaid (Fig 2, Column 3, Rows a and b). In contrast, in the cells in late prophase, prothymosin
appeared to be more diffuse than the brighter condensing DNA. When the images of prothymosin
and DNA were superimposed, it was dramatically clear in Fig 2, Row b (less so in row a) that a significant portion of prothymosin
was extranuclear well before the onset of prometaphase when the nuclear envelope breaks down. Later, in metaphase (Fig 2, Rows c and d), we were not surprised to find prothymosin
dispersed throughout the cell but virtually excluded from the metaphase plate. Throughout anaphase (Fig 2, Rows eg), prothymosin
remained diffuse in the cell and continued to be excluded from the volume occupied by DNA. Finally, the location of prothymosin
was compared to that of chromatin at early telophase (Fig 2, Row h). Prothymosin
was vastly underrepresented in the region occupied by the newly forming nucleus. These data focus attention on the fact that prothymosin
can be found in the cytoplasm not only at mitosis, when the nuclear envelope ceases to exist, but also before the envelope breaks down and after it reforms. Therefore, prothymosin
is not exclusively nuclear.
Effect of Metabolic Inhibitors on the Distribution of Prothymosin /6-his
The presence of prothymosin in the cytoplasm of prometaphase cells raised questions about the location of the protein during interphase. Careful examination of cycling cells revealed labeled prothymosin
/6-his in the cytoplasm at levels too high to be attributed to background. Furthermore, the stain was not evenly dispersed throughout but appeared to be somewhat concentrated in a halo surrounding the nucleus (Fig 1b and Fig 3a). Because protein synthesis is a cytoplasmic event, all newly synthesized proteins must traverse the cytoplasm en route to their final abode. We considered the possibility that cytoplasmic prothymosin
was no more than a reflection of this process. Accordingly, cells were transfected with prothymosin ß/6-his DNA, incubated for 6 hr, and treated with cycloheximide (Fig 3b) or actinomycin D (Fig 3c) for 2 hr to shut down protein synthesis and RNA synthesis, respectively. As shown in Fig 3, these metabolic inhibitors, which themselves do not interfere with nuclear import (
. Hence, prothymosin
molecules in the cytoplasm are not necessarily new. The possibility that a subset of prothymosin
is cytoplasmic or that the protein shuttles between the nuclear and cytoplasmic compartments had to be seriously considered.
Effect of Blocking Nuclear Import on the Distribution of Prothymosin
Entry into the nucleus through the nuclear pore is a two-step process. In the first step, cytosolic proteins recognize and bind to the nuclear localization signal, forming a transport complex which docks with fibrils of the nuclear pore. In a second step, translocation through the pore complex occurs in an energy-dependent manner requiring the net hydrolysis of both ATP and GTP (reviewed in /6-his and other endogenous nuclear proteins can no longer transit to the nucleus. Three different proteins in two transfection experiments were examined. In the first transfection, prothymosin
/6-his DNA was introduced into COS cells and the product was visualized with rhodamine-conjugated secondary antibody (red), while endogenous Ran was examined with fluorescein-conjugated secondary antibody (green) in the same cells. In the second transfection, the much larger prothymosin
/ß-gal, which was also visualized with rhodamine-conjugated secondary antibody, was the test protein (Fig 4). Ran was chosen as the endogeneous protein for comparison because it is small, it shuttles between nucleus and cytoplasm and, as a component of the nuclear transport apparatus, it must interact transiently with transport complexes bearing cargo proteins such as prothymosin
. At the initiation of the experiment when the cells remained at 37C, prothymosin
/6-his and Ran were predominantly massed in the nucleus, with only a trace of each in the cytoplasm. Prothymosin
/ß-gal appeared to be virtually exclusively nuclear, as reported previously (
/6-his and Ran moved into the cytoplasm in a time-dependent manner (Fig 4, Rows 1 and 2, Columns 2 and 3). In contrast, the prothymosin
/ß-gal chimera was unaffected by the shift in temperature. No movement into the cytoplasm was detected and the tell-tale traces of cytoplasmic prothymosin
were absent (Fig 4, Row 3, Column 3). When the cooled cells were warmed to 37C, virtually all molecules of both prothymosin
/6-his and Ran reentered the nucleus within the 30-min test period (Fig 4, Column 4). In these experiments, Ran, which functions as a control protein, behaved as expected by accumulating in the cytoplasm under conditions in which entry into the nucleus was abrogated. Therefore, the data suggest that prothymosin
is also able to leave the nucleus and that its nuclear localization requires continuous re-entry. Furthermore, the data show that egress is not simply a function of prothymosin
sequences because both prothymosin
/6-his, which escapes from the nucleus, and prothymosin
/ß-gal, which remains, have the prothymosin
moiety in common. We infer that the small size of native prothymosin
is essential for its mobility and that prothymosin
with an adduct the size of bacterial ß-galactosidase passes unidirectionally into the nucleus.
We also investigated the fate of prothymosin /6-his when nuclear import was prevented with a different technique. Cells were permeabilized with
-toxin (
S and GTP
S to inhibit the energy-dependent component of protein uptake by the nucleus (
-toxin but not with the analog inhibitors, was stained with DAPI (Fig 5a) and with antibodies to Ran (TRITC), and prothymosin
/6-his (FITC) (Fig 5b and Fig 5c). Because the DAPI stain delineates the nucleus, it is clear that prothymosin
/6-his and Ran, although overwhelmingly nuclear, also populate the cytosol to a limited extent. Because this pattern has already been demonstrated in intact cells for both proteins (see Fig 4, Column 1), exposure to the toxin apparently did not affect the integrity of the nucleus or the preferred position of the two proteins. Under these conditions, it was possible to examine the effect of the analogue inhibitors in a second cell, shown in Fig 5d5f. Here, both prothymosin
/6-his (Fig 5f) and Ran (Fig 5e) no longer reside almost exclusively in the nucleus. The FITC and TRITC labels, indicating the positions of the proteins, extend well beyond the volume occupied by the DAPI-stained DNA. Hence, a significant fraction of both proteins became cytosolic. The data corroborate the results of the cooling experiment: the nuclear localization of prothymosin
depends on repeated import into the nucleus. It is also obvious that the two proteins overlap in their distribution. This point becomes important, below, when the function of prothymosin
is addressed.
The Distribution of Prothymosin in Digitonin-treated Cells
The ability of prothymosin molecules to diffuse rapidly throughout most of the nucleus and the cytoplasm could obscure a small confined pool of the protein located at its principal sites of activity. To identify such putative pools, we sought to deplete the nucleus of the mobile component of prothymosin
by treating the cells with digitonin. This technique, which perforates the plasma membrane, can remove almost all of the prothymosin
from a cell in a time- and dose-dependent manner. Digitonin treatment is also the preferred technique for generating systems for investigating nuclear transport, preparations known to be deficient in Ran (
in digitonin-treated cells. The results shown in Fig 6 present the same cell with FITC-stained Ran, TRITC-stained prothymosin
/6-his, and DNA stained with DAPI to define the boundaries of the nucleus. Although the particular cell chosen retained significant quantities of Ran in the nucleus, prothymosin
/6-his was completely absent; the photograph was overexposed so that the background red color would mark the nuclear outline. Despite the retention of Ran in the nucleus, which varied from nearly normal to barely detectable (data not shown), prothymosin
was quantitatively released. This experiment shows that prothymosin
is even more poorly anchored in the nucleus than Ran and suggests that neither prothymosin
in general nor a putative subset engages in tight binding to other subnuclear modules. Our data are consistent with the idea that the mobility of prothymosin
is important for its activity and that the domain in which it functions encompasses both the nucleus and the nearby surrounding cytosol.
Comparison of the Nuclear Position of Prothymosin with That of Other Nuclear Proteins
Although our data were not consistent with the stable association of prothymosin with any macromolecule, we nevertheless sought to discover whether it co-localized with well characterized nuclear molecules. To this end, we acquired a panel of antibodies that recognized proteins with different functions and different positions within the nucleus and we compared the location of histidine-tagged prothymosin
, stained with TRITC, with that of the selected second protein stained with FITC. We chose histone H1 for comparison because
reorganizes chromatin into a more active configuration by binding to and depleting histone H1. This view is supported by two studies that demonstrated the binding of the two proteins in vitro (
/6-his and histone H1 were broadly distributed in the nucleus and that histone H1 was extremely abundant. It is also clear that only a fraction of the two proteins co-localized, as indicated by a dearth of yellow denoting close juxtaposition of one with the other. Furthermore, when the image was manipulated to remove a wedge of histone H1 (FITC) in order to emphasize the TRITC stain of tagged prothymosin
, it became obvious that histone H1 extended to the periphery of the nucleus, whereas prothymosin
was concentrated more centrally. The image makes clear that a surfeit of green color had not simply obliterated the scarcer prothymosin
in red. These images are difficult to reconcile with a functional interaction. Presumably, even a transient interaction would require the distribution of the peripheral histone H1 to overlap with that of prothymosin
.
Using an antibody to SC-35, we investigated the location of prothymosin /6-his with respect to that of splicing factors in regions microscopically characterized as "speckled domains." It is largely accepted that the speckled domains constitute storage depots for splicing factors; there is also evidence that these domains include staging areas for RNAs destined for export (reviewed in
binds to the leucine motif/activation domains of HTLV-I Rex and HIV-1 Rev in vitro (
in the vicinity of the speckled domains. As shown in Fig 7b, there was clearly a restricted distribution of SC-35 protein in the nucleus, as previously noted. More importantly, prothymosin
appeared to be abundant only in the regions separating the SC-35-stained domains. Not only were the speckled domains virtually free of prothymosin
but also there was no accumulation of prothymosin
at their perimeters. Such data do not support a direct role for prothymosin
in the recruitment or assembly of splicing factors.
The next pairwise comparison was carried out with antibodies against the phosphorylated C-terminal domain of RNA polymerase II ( is curtailed during mitosis and also in the presence of actinomycin D in NIH3T3 cells (
and ongoing transcription. At first glance, Fig 7c appears to corroborate this view. The tagged prothymosin
(TRITC) was much more plentiful than the active polymerase II molecules illuminated by the FITC-conjugated antibody; hence, there was widely distributed rhodamine fluorescence in the nucleus. In contrast, there was almost no green fluorescein fluorescence; the vast majority of polymerase II molecules were yellow, indicating co-localization with prothymosin
. Although one might infer a role for prothymosin
in the synthesis of mRNA from such co-localization data, the images to be presented below require a different, broader interpretation. A more global view of prothymosin
is also supported by quantitative assessments: there are ~105 growing transcripts of RNA in a HeLa cell (
prevalence in a myeloma cell probably exceed 30 x 106 (
In Fig 7d7f, the location of prothymosin was compared pairwise with that of Ran, transportin, or karyopherin ß, respectively. Each of these proteins is abundant, involved with transport through the nuclear pore, highly mobile (reviewed in
. Ran, which is more abundant that the tagged prothymosin
but fairly equivalent in amount to the native prothymosin
in the cell, appeared mostly isolated from prothymosin
, but a significant portion was yellow. Prothymosin
was represented by rhodamine speckles and also by yellow, a clear indication that a part, but not the totality, of the two populations co-localized (Fig 7d). In contrast, co-localization of prothymosin
(red) with either transportin (Fig 7e) or karyopherin ß (Fig 7f) was extensive, with a rhodamine tinge in Fig 7e denoting a slight excess of stained prothymosin
, whereas the fluorescein cast in Fig 7f was consistent with a tiny excess of stained karyopherin ß. The data indicate that prothymosin
is found close to an array of molecules that depend on mobility to execute their functions.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Our study explores the position of epitope-tagged prothymosin in transfected cells as a means of directing attention towards processes in which the native protein may participate. Our data strongly suggest that prothymosin
, together with other highly diffusible molecules, resides predominantly in the nucleus in a domain characterized by internal fluidity, that there is measurable efflux into the cytosol, and that prothymosin
maintains its nuclear localization by continuous uptake through the nuclear pore. These conclusions are supported by a number of findings.
In lysed, disrupted, or leaky cells, prothymosin is released into the cytoplasm. The ability to recover prothymosin
in post-nuclear supernatants of detergent-lysed cells was demonstrated in 1990 by Sburlati et al., who first determined the abundance of the protein and later quantitatively recovered it in the soluble fractions of the cell. Similarly, digitonin treatment, which primarily affects the integrity of the plasma membrane, resulted in the depletion of tagged and native prothymosin
from all nuclei and a somewhat variable loss of Ran, a small GTP-binding protein required for transport of macromolecules through the nuclear pore. In contrast, cells treated with cytochalasin to solubilize actin filaments and centrifuged to cause enucleation retain prothymosin
within their nuclei. A fragment of plasma membrane seals each nucleus and prevents leakage of small molecules, including prothymosin
(
is sufficiently mobile to diffuse rapidly from its initial location in the nucleus throughout the liquid phase unless plasma membranes intervene.
Prothymosin is almost entirely nuclear in normal cells but exhibits a small, reproducible cytoplasmic presence. Using in situ immunolocalization techniques, together with specific antibodies that recognize both large and small epitope tags on prothymosin
, we have localized tagged prothymosin
primarily to the nucleus. However, further examination of our preparations revealed significant quantities of histidine-tagged prothymosin
in the cytosol in prometaphase cells as well as those in late telophase; a bias towards a perinuclear distribution was evident. Careful consideration of intact interphase cells using the same reagents confirmed the existence of extranuclear, small, tagged prothymosin
, exemplified by the histidine-tagged molecules. The cytoplasmic molecules persisted in the presence of actinomycin D and, more importantly, cycloheximide, a finding suggesting that newly synthesized prothymosin
molecules en route to a nuclear domain as well as mature molecules constitute the cytoplasmic pool. Hence, the data validate the presence of prothymosin
outside the nucleus.
In metabolically compromised cells, the cytoplasmic pool of prothymosin becomes significant. Two techniques that abrogate nuclear uptake of proteinscooling cells to 0C and blocking the energy-dependent step of transport with inhibitory levels of ATP
S and GTP
S intracellularly (
to accumulate in the cytoplasm; prothymosin
/ß-gal, evidently, was too large to escape from the nucleus. These data strongly suggest that the ability of the nucleus to concentrate native prothymosin
depends on the protein's potent nuclear localization signal (
Finally, two further observations support our view of prothymosin as an unfettered, mobile molecule. Attempts to immunoprecipitate prothymosin
tagged with the FLAG epitope in the presence of a high concentration of calcium did not succeed in identifying specific binding partners (Manrow, unpublished data). Moreover, attempts to crosslink reactive forms of prothymosin
and histidine-tagged prothymosin
in situ failed to distinguish neighboring molecules. In the most extensive of these experiments, histidine-tagged prothymosin
was covalently attached to sulfosuccinimidyl 2-[7-azido-4-methylcoumarin-3-acetamide]ethyl-1,3'-dithiopropinate (SAED) in the dark, the compound was forced into cells by electroporation, and the reactive moiety was light-activated only after large quantities of the construct had attained the nucleus. No crosslinked partners were exposed (R.-H. Wang and S. L. Berger, unpublished data). Hence, the biochemical evidence and the imaging studies document the extraordinary ability of prothymosin
to disperse throughout much of the nucleus, to exit into the perinuclear space under normal conditions, and to accumulate in the cytosol when nuclear re-entry is obstructed.
Few proteins are known to travel freely through the nucleus. Because all proteins arise in the cytoplasm, they evidently enter the nucleus with or without an escort and proceed to the sites at which they function. Mounting evidence suggests that signal sequences direct proteins to find and associate with subnuclear compartments (reviewed in , which shares a soluble domain with karyopherin ß, transportin, and Ran.
Our experiments show that a subset of prothymosin co-localized with active RNA polymerase II. This finding is important because we have postulated a role for prothymosin
in transcription based on the ability of actinomycin D to obstruct turnover of prothymosin
's glutamyl phosphates in NIH3T3 cells (
, yet the drug is known to cause structural changes in the nucleus, including chromatin remodeling, coalescence of speckled domains into larger clusters, and redistribution of transcriptionally active polymerase II (
remained unchanged despite alterations in other components of the transcriptional machinery, we infer that the role of prothymosin
in transcription is ancillary. Furthermore, with a concentration of native prothymosin
hundreds of times higher than that of polymerase II in a normal nucleus, the data suggest that prothymosin
has responsibilities that extend well beyond the polymerization of RNA.
Here we propose a model of the nucleus that includes prothymosin . However, before demonstrating how prothymosin
's characteristics can be incorporated into nuclear activities, it might be useful to eliminate putative functions that are not consistent with the data in this communication. We have found that prothymosin
does not co-localize with histone H1 located near the nuclear membrane and co-localizes poorly with chromatin. Hence, functions including nucleosome assembly and chromatin remodeling (
is involved in splicing; the speckled domains illuminated with antibodies against SC-35 (
. Similarly, the extreme fluidity of intracellular prothymosin
is difficult to reconcile with the observed in vitro binding of prothymosin
via its amino groups to peptides representing the conserved leucine-motif/activation domains of the viral proteins HIV rev and HTLV rex. Our data strongly suggest that stable binding is not a characteristic of prothymosin
regardless of the putative binding partner.
Any model that purports to explain the function of prothymosin must account for the apparent paradox of a highly negatively charged protein that becomes transiently even more negatively charged by the acquisition of high-energy glutamyl phosphates while remaining mobile in the nucleus. The model must also accommodate an abundant molecule with an unfolded conformation. Indeed, the very floppiness of prothymosin
implies broad specificity rather than a lock-and-key fit with a limited number of partners. Therefore, we suggest that the mobility of prothymosin
is its function and that this attribute acquires meaning in the context of an intact nucleus where, deep within interior crevices, electrostatic barriers to free movement of large and small molecules abound. We propose that prothymosin
maintains the flow of molecules by repelling negatively charged molecules and by binding to positively charged ones. Furthermore, because stable binding to any macromolecule apparently does not occur, we invoke the known rapid turnover of glutamyl phosphates (
resists becoming electrostatically trapped. Although such a mechanism is far from proven, it is tempting to speculate that high-energy glutamyl phosphates are either hydrolyzed to allow movement or perhaps are transiently transferred to positively charged groups to promote a more neutral environment. Restated, we believe that prothymosin
facilitates movement not only of itself but also of other molecules into and within the nucleus, particularly in highly charged environments. If one thinks of a finished nucleus with basic proteins bound to RNAs and basic histones associated with DNA, one might doubt the need for a facilitator molecule to overcome electrostatic interactions. With a plethora of competing charged moieties in the nucleus, our approach is to wonder how those very highly charged molecules get together correctly in the first place.
![]() |
Footnotes |
---|
1 Present address: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
![]() |
Acknowledgments |
---|
We thank Richard E. Manrow of the National Cancer Institute for the use of pFLAG60, which he fabricated while employed as a member of this laboratory. We would also like to thank Dr Carolyn L. Smith of the National Institute of Neurological Diseases and Stroke and Dr John A. Hanover of the National Insititute of Diabetes and Digestive and Kidney Diseases for their help on separate occasions with confocal microscopy.
Received for publication May 10, 2000; accepted May 17, 2000.
![]() |
Literature Cited |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Adam SA, Marr RS, Gerace L (1990) Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors. J Cell Biol 111:807-816[Abstract]
Auger C, Stahli C, Fabien N, Monier J-C (1987) Intracellular localization of thymosin alpha 1 by immunoelectron microscopy using a monoclonal antibody. J Histochem Cytochem 35:181-187[Abstract]
Bhakdi S, Weller U, Walev I, Martin E, Jonas D, Palmer M (1993) A guide to the use of pore-forming toxins for controlled permeabilization of cell membranes. Med Microbiol Immunol (Berl) 182:167-175[Medline]
Breeuwer M, Goldfarb DS (1990) Facilitated nuclear transport of histone H1 and other small nucleophilic proteins. Cell 60:999-1008[Medline]
Bregman DB, Du L, van der Zee S, Warren SL (1995) Transcription-dependent redistributionof the large subunit of RNA polymerase II to discrete nuclear domains. J Cell Biol 129:287-298[Abstract]
Bustelo XR, Otero A, GómezMárquez J, Freire M (1991) Expression of the rat prothymosin alpha gene during T-lymphocyte proliferation and liver regeneration. J Biol Chem 266:1443-1447
Carter KC, Bowman D, Carrington W, Fogarty K, McNeil JA, Fay FS, Lawrence JB (1993) A three-dimensional view of precursor messenger RNA metabolism within the mammalian nucleus. Science 259:1330-1335[Medline]
Clinton M, Graeve L, El-Dorry H, RodriguezBoulan E, Horecker BL (1991) Evidence for nuclear targeting of prothymosin and parathymosin synthesized in situ. Proc Natl Acad Sci USA 88:6608-6612[Abstract]
Conteas CN, Mutchnick MG, Palmer KC, Weller FE, Luk GD, Naylor PH, Erdos MR, Goldstein AL, Panneerselvam C, Horecker BL (1990) Cellular levels of thymosin immunoreactive peptides are linked to proliferative events: evidence for a nuclear site of action. Proc Natl Acad Sci USA 87:3269-3273[Abstract]
DíazJullien C, PérezEstévez A, Covelo G, Freire M (1996) Prothymosin alpha binds histones in vitro and shows activity in nucleosome assembly assay. Biochim Biophys Acta 1296:219-227[Medline]
Enkemann SA, Pavur KS, Ryazanov AG, Berger SL (1999) Does prothymosin alpha affect the phosphorylation of elongation factor 2? J Biol Chem 274:18644-18650
Eschenfeldt WH, Berger SL (1986) The human prothymosin alpha gene is polymorphic and induced upon growth stimulation: evidence using a cloned cDNA. Proc Natl Acad Sci USA 83:9403-9407[Abstract]
Eschenfeldt WH, Manrow RE, Krug MS, Berger SL (1989) Isolation and partial sequencing of the human prothymosin alpha gene family. J Biol Chem 264:7546-7555
Finlay DR, Newmeyer DD, Hartl PM, Horecka J, Forbes DJ (1989) Nuclear transport in vitro. J Cell Sci Suppl 11:225-242[Medline]
Fraga M, GarcíaCaballero T, Domínguez F, PérezBecerra E, Beiras A, Forteza J (1993) Immunohistochemical location of prothymosin in regenerating human hepatocytes and hepatocellular carcinomas. Virchows Arch 423:449-452. [A]
FrangouLazaridis M, Clinton M, Goodall GJ, Horecker BL (1988) Prothymosin alpha and parathymosin: amino acid sequences deduced from the cloned rat spleen cDNAs. Arch Biochem Biophys 263:305-310[Medline]
Gannon JV, Lane DP (1991) Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature 349:802-806[Medline]
Gast K, Damaschun H, Eckert K, SchulzeForster K, Maurer HR, MüllerFrohne M, Zirwer D, Czarnecki J, Damaschun G (1995) Prothymosin alpha: a biologically active protein with random coil conformation. Biochemistry 34:13211-13218[Medline]
Goldstein AL, Low TLK, McAdoo M, McClure J, Thurman GB, Rossio J, Lai C-Y, Chang D, Wang SS, Harvey C, Ramel AH, Meienhofer J (1977) Thymosin 1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA 74:725-729[Abstract]
GómezMárquez J, Rodríguez P (1998) prothymosin alpha is a chromatin-remodelling protein in mammalian cells. Biochem J 333:1-3[Medline]
GómezMárquez J, Segade F, Dosil M, Pichel JG, Bustelo XR, Freire M (1989) The expression of prothymosin alpha gene in T lymphocytes and leukemic lymphoid cells is tied to lymphocyte proliferation. J Biol Chem 264:8451-8454
Goodall GJ, Domínguez F, Horecker BL (1986) Molecular cloning of cDNA for human prothymosin alpha. Proc Natl Acad Sci USA 83:8926-8928[Abstract]
Haritos AA, Blacher R, Stein S, Caldarella J, Horecker BL (1985) Primary structure of rat thymus prothymosin alpha. Proc Natl Acad Sci USA 82:343-346[Abstract]
Haritos AA, Goodall GJ, Horecker BL (1984) Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin 1 in rat thymus. Proc Natl Acad Sci USA 81:1008-1011[Abstract]
Jackson DA, Iborra FJ, Manders EM, Cook PR (1998) Numbers and organization of RNA polymerases, nascent transcripts, and transcription units in HeLa nuclei. Mol Biol Cell 9:1523-1536
Karetsou Z, Sandaltzopoulos R, FrangouLazaridis M, Lai C-Y, Tsolas O, Becker PB, Papamarcaki T (1998) Prothymosin alpha modulates the interaction of histone H1 with chromatin. Nucleic Acids Res 26:3111-3118
Kozak M (1986) Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44:283-292[Medline]
Kozak M (1987) At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 196:947-950[Medline]
Kubota S, Adachi Y, Copeland TD, Oroszlan S (1995) Binding of human prothymosin alpha to the leucine-motif/activation domains of HTLV-I rex and HIV-1 rev. Eur J Biochem 233:48-54[Abstract]
Leonhardt H, Cardoso MC (1995) Targeting and association of proteins with functional domains in the nucleus: the insoluble solution. Int Rev Cytol 162B:303-335
Makarova T, Grebenshikov N, Egorov C, Vartapetian A, Bogdanov A (1989) Prothymosin alpha is an evolutionary conserved protein covalently linked to a small RNA. FEBS Lett 257:247-250[Medline]
Manrow RE, Sburlati AR, Hanover JA, Berger SL (1991) Nuclear targeting of prothymosin alpha. J Biol Chem 266:3916-3924
Melchior F, Paschal B, Evans J, Gerace L (1993) Inhibition of nuclear protein import by nonhydrolyzable analogues of GTP and identification of the small GTPase, Ran/TC4, as an essential transport factor. J Cell Biol 123:1649-1659[Abstract]
Michalewsky J, Gabriel TF, Winter DP, Makofske R, Danho W, Shively J, Biemann K, Meienhofer J (1983) Confirmation of the primary structure of thymosin 1 by microsequence analysis of limited acid and enzymatic hydrolysis fragments. J Pept Prot Res 21:93-99
Moroianu J, Blobel G (1995) Protein export from the nucleus requires the GTPase, Ran, and GTP hydrolysis. Proc Natl Acad Sci USA 92:4318-4322[Abstract]
Oates KK, Erdos M (1989) Biochemical identification of thymosin alpha-1: its phylogenetic distribution and evolutionary implications. Comp Biochem Physiol 94B:759-763
Ohno M, Fornerod M, Mattaj IW (1998) Nucleocytoplasmic transport: the last 200 nanometers. Cell 92:327-336[Medline]
Palvimo J, Linnala-Kankkunen A (1990) Identification of a low-Mr acidic nuclear protein as prothymosin alpha. FEBS Lett 277:257-260[Medline]
Panneerselvam C, Haritos AA, Caldarella J, Horecker BL (1987) Prothymosin alpha in human blood. Proc Natl Acad Sci USA 48:4465-4469
Panneerselvam C, Wellner D, Horecker BL (1988) The amino acid sequence of bovine thymus prothymosin alpha. Arch Biochem Biophys 250:197-201
Papmarcaki T, Tsolas O (1994) Prothymosin alpha binds to histone H1 in vitro. FEBS Lett 345:71-75[Medline]
Pemberton LF, Blobel G, Rosenblum JS (1998) Transport routes through the nuclear pore complex. Curr Opin Cell Biol 10:392-399[Medline]
PinolRoma S, Dreyfuss G (1991) Transcription-dependent and transcription-independent nuclear transport of hnRNP proteins. Science 253:312-314[Medline]
Richardson WD, Mills AD, Dilworth SM, Laskey RA, Dingwall C (1988) Nuclear protein migration involves two steps: rapid binding at the nuclear envelope followed by slower translocation through nuclear pores. Cell 52:655-664[Medline]
Sburlati AR, De La Rosa A, Batey DW, Kurys GL, Manrow RE, Pannell LK, Martin BM, Sheeley DM, Berger SL (1993) Phosphorylation of human and bovine prothymosin alpha in vivo. Biochemistry 32:4587-4596[Medline]
Sburlati AR, Manrow RE, Berger SL (1990) Human prothymosin alpha: purification of a highly acidic nuclear protein by means of a phenol extraction. Protein Express Purif 1:184-190[Medline]
Schmidt G, Werner D (1991) Nucleotide sequence of the murine prothymosin alpha cDNA and its deduced primary and secondary protein structure. Biochim Biophys Acta 1088:442-444[Medline]
Spector DL (1993) Macromolecular domains within the cell nucleus. Annu Rev Cell Biol 9:265-315
Spector DL (1996) Nuclear organization and gene expression. Exp Cell Res 229:189-197[Medline]
Spector DL, Fu X-D, Maniatis T (1991) Associations between distinct premRNA splicing components and the cell nucleus. EMBO J 10:3467-3481[Abstract]
Szabo P, Weksler ME (1992) Is thymosin 1 a thymic hormone? Clin Immunol Immunopathol 65:195-200[Medline]
Tao L, Wang R-H, Enkemann SA, Trumbore MW, Berger SL (1999) Metabolic regulation of protein-bound glutamyl phosphates: insights into the function of prothymosin alpha. J Cell Physiol 178:154-163[Medline]
Trumbore MW, Manrow RE, Berger SL (1998) Prothymosin alpha is not found in yeast. Prot Express Purif 13:383-388[Medline]
Trumbore MW, Wang R-H, Enkemann SA, Berger SL (1997) Prothymosin alpha in vivo contains phosphorylated glutamic acid residues. J Biol Chem 272:26394-26404
Tsitsiloni LE, Yialouris PP, SekeriPataryas K, Haritos AA (1989) Prothymosin alpha is not a nuclear polypeptide. Experientia 45:332-334[Medline]
Tsitsiloni OE, Stiakakis J, Koutselinis A, Gogas J, Markopoulos C, Yialouris P, Bekris S, Panoussopoulos D, Kiortsis V, Voelter W, Haritos AA (1993) Expression of -thymosins in human tissues in normal and abnormal growth. Proc Natl Acad Sci USA 90:9504-9507[Abstract]
Vartapetian A, Makarova TN, Koonin E, Agol VI, Bogdanov AA (1988) Small cytoplasmic RNA from mouse cells covalently linked to a protein. FEBS Lett 232:35-38[Medline]
Vega FV, Vidal A, Hellman U, Wernstedt C, Domínguez F (1998) Prothymosin alpha stimulates Ca2+-dependent phosphorylation of elongation factor 2 in cellular extracts. J Biol Chem 273:10147-10152
Wang R-H, Tao L, Trumbore MW, Berger SL (1997) Turnover of the acyl phosphates of human and murine prothymosin alpha in vivo. J Biol Chem 272:26405-26412
Watts JD, Cary P, CraneRobinson C (1989) Prothymosin alpha is a nuclear protein. FEBS Lett 245:17-20[Medline]
Watts JD, Cary P, Sautiere P, CraneRobinson C (1990) Thymosins: both nuclear and cytoplasmic proteins. Eur J Biochem 192:643-651[Abstract]
Xing Y, Johnson CV, Dobner PR, Lawrence JB (1993) Higher level organization of individual gene transcription and RNA splicing. Science 259:1326-1330[Medline]